Tamoxifen: A most unlikely pioneering medicine

Nature Reviews Drug Discovery

Volumn 2, Issue 3, 2003, Pages 205-213

  Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CHLOROTRIANISENE; CLOMIFENE; CLOMIFENE CITRATE; DROLOXIFENE; ESTROGEN RECEPTOR; ETHAMOXYTRIPHETOL; FULVESTRANT; GLUCOCORTICOID; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NAFOXIDENE; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE; TRIPARANOL; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SURVIVAL; CATARACT; CATARACTOGENESIS; CHEMOPROPHYLAXIS; DRUG APPROVAL; ENDOMETRIUM CANCER; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; NONHUMAN; OUTCOMES RESEARCH; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION; ANIMAL; BREAST TUMOR; DRUG DESIGN; FEMALE; HISTORY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG DESIGN; ESTROGEN ANTAGONISTS; FEMALE; HISTORY, 20TH CENTURY; HUMANS; TAMOXIFEN;

EID: 0037364074     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1031     Document Type: Review

References (96)

1. Baumler, E. Paul Ehrlich: Scientist for Life (Holmes & Meier, New York, 1984).
2. Harper, M. J. & Walpole, A. L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212, 87 (1966).
3. Harper, M. J. & Walpole, A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil. 13, 101-119 (1967).
4. Harper, M. J. & Walpole, A. L. Mode of action of I. C. I. 46,474 in preventing implantation in rats. J. Endocrinol. 37, 83-92 (1967).
5. Cole, M. P., Jones, C. T. & Todd, I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer 25, 270-275 (1971).
6. Ward, H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J. 1, 13-14 (1973).
7. Ingle, J. N. et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer N. Engl. J. Med. 304, 16-21 (1981).
8. Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2, 104-107 (1896).
9. Boyd, S. On oophorectomy in cancer of the breast. BMJ 2, 1161-1167 (1900).
10. Lathrop, A. E. & Loeb, L. Further investigations on the origins of tumors in mice III on the part played by internal secretions in the spontaneous development of tumors. J. Cancer Res. 1, 1-19 (1916).
11. Lacassagne, A. Hormonal pathogenesis of adenocarcinoma of the breast. Am. J. Cancer 27, 217-225 (1936).
12. Lerner, L. J. in Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity (eds. Sutherland, R. L. & Jordan, V. C.) 1-6 (Sydney Academic Press, Sydney, Australia, 1981).
13. Lerner, L. J., Holthaus, J. F. & Thompson, C. R. A non-steroidal estrogen antagonist 1-(p-2-diethylamino-ethoxyphenyl)-1-phenyl-2-p-methoxyphenylethanol. Endocrinology 63, 295-318 (1958).
14. Duncan, G. W., Lyster, S. C., Clark, J. J. & Lednicer, D. Antifertility activities of two diphenyl-dihydroaphthalene derivatives. Proc. Soc. Exp. Biol. Med. 112, 439-442 (1963).
15. Legha, S. S., Slavik, M. & Carter, S. K. Nafoxidine - an antiestrogen for the treatment of breast cancer. Cancer 38, 1535-1541 (1976).
16. Holtkamp, D. E., Greslin, S. C., Root, C. A. & Lerner, L. J. Gonadotropin inhibiting and antifecundity effects of chloramiphene. Proc. Soc. Exp. Biol. Med. 105, 197-201 (1960).
17. Greenblatt, R. B., Barfield, W. E., Jungck, E. C. & Ray, A. W. Induction of ovulation with MRL-41 - Preliminary Report. JAMA 178, 101-104 (1961).
18. Greenblatt, R., Roy, S. & Mahesh, V. The induction of ovulation. Am. J. Obstet. Gynecol. 84, 900-912 (1962).
19. Whitelaw, M. J. Clomiphene citrate experience with 217 patients. Fertil. Steril. 17, 584-604 (1966).
20. Herbst, A. L., Griffiths, C. T. & Kistner, R. W. Clomiphene citrate (NSC-35770) in disseminated mammary carcinoma. Cancer Chemother. Rep. 43, 39-41 (1964).
21. Bloom, H. J. G. & Boesch, E. Antioestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases. Br. Med. J. 2, 7-12 (1974).
22. William S. Merrel Company. Official Literature on New Drugs: Clomiphene citrate (Clomid). Clin. Pharmacol. Ther. 8, 891-897 (1967).
23. Hollander, W., Chobanian, A. V. & Wilkins, R. W. The effects of triparanol (MER-29) in subjects with and without coronary artery disease. JAMA 174, 87-94 (1960).
24. Laughlin, R. C. & Carey, T. F. Cataracts in patients treated with triparanol. JAMA 181, 369-370 (1962).
25. Avigan, J., Steinberg, D., Vroman H. E., Thompson, M. J. & Mosettig, E. Studies of cholesterol biosynthesis. The identification of desmosterol in serum and tissues of animals and man treated with MER29. J. Biol. Chem. 235, 3123-3126 (1960).
26. Kraft, R. O. Triparanol in the treatment of disseminated mammary carcinoma. Cancer Chemother. Rep. 25, 113-115 (1962).
27. Haddow, A., Watkinson, J. M. & Paterson, E. Influence of synthetic oestrogens upon advanced malignant disease. BMJ 2, 393-398 (1944).
28. Walpole, A. L. & Paterson, E. Synthetic oestrogens in mammary cancer. Lancet 2, 783-789 (1949).
29. Bedford, G. & Richardson, D. N. Preparation and identification of cis and trans isomers of a substituted triphenylethylene. Nature 212, 733-734 (1966).
30. Kilbourn, B., Mais, R. H. B. & Owston, P. G. Identification of isomers of a substituted triphenylethylene: the crystal structure of 1-p-(2-dimethylaminoethoxyphenyl)1,2 cis diphenyl but1-ene hydrobromide. Chem. Commun. 1, 291 (1968).
31. Labhsetwar, A. P. Role of oestrogen in spontaneous ovulation demonstrated by use of an antagonist of oestrogen ICI46,474. Nature 225, 80-81 (1970).
32. Labhsetwar, A. P. Role of estrogen in ovulation a study using estrogen antagonist ICI46,474. Endocrinology 87, 542-551 (1970).
33. Labhsetwar, A. P. Effects of antioestrogen on the corpus luteum of rabbits and rats. J. Reprod. Fertil. 25, 295-297 (1971).
34. Labhsetwar, A. P. Role of estrogen in spontaneous ovulation: evidence for positive feedback in hamsters. Endocrinology 90, 941-946 (1972).
35. Jordan, V. C. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res. Treat. 11, 197-209 (1988).
36. Klopper, A. & Hall, M. New synthetic agent for the induction of ovulation. Preliminary trial in women. Br. Med. J. 1, 152-154 (1971).
37. Williamson, J. G. & Ellis, J. D. The induction of ovulation by tamoxifen. J. Obstet. Gynaecol. Br Commonwealth 80, 844-847 (1973).
38. El-Sheikha, Z., Klopper, A. & Beck, J. S. Treatment of menometrorrhagia with an anti-oestrogen. Clin. Endocrinology 1, 275-282 (1972).
39. Palopoli, F. P., Feil, V. J., Allen, R. F., Holtkamp, D. E., and Richardson Jr., A. Substituted aminoalkoxyl-triarylhaloethylenes. J. Med. Chem. 10, 84-86 (1967).
40. Ernst, S., Hite, G., Cantrell, J. S., Richardson Jr, A. & Benson, H. D. Stereochemistry of geometric isomers of clomiphene: a correction of structure-activity relationships. J. Pharm. Sci. 65, 148-150 (1976).
41. Emmens, C. W. Postcoital contraception. Br. Med. Bull. 26, 45-51 (1970).
42. Lunan, C. B. & Klopper, A. Antioestrogens: a review. Clin. Endocrinology 4, 551-572 (1975).
43. Huggins, C., Grand, L. C. & Brillantes, F. P. Mammary cancer induced by a single feeding of polynuclear hydrocarbons and their suppression. Nature 189, 204 (1961).
44. Jensen, E. V. & Jacobson, H. I. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 18, 387-414 (1962).
45. Jensen, E. V., Block, G. E., Smith, S., Kyser, K. & DeSombre, E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst. Monogr. 34, 55-70 (1971).
46. Skidmore, J. R., Walpole, A. L. & Woodburn, J. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J. Endocrinol. 52, 289-298 (1972).
47. Jordan, V. C., Collins, M. M., Rowsby, L. & Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305-316 (1977).
48. Allen, K. E., Clark, E. R. & Jordan, V. C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br. J. Pharmacol. 71, 83-91 (1980).
49. Jordan, V. C. & Koerner, S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur. J. Cancer. 11, 205-206 (1975).
50. Nicholson, R. I. & Golder, M. P. The effect of synthetic antioestrogens on the growth and biochemistry of rat mammary tumours. Eur. J. Cancer 11, 571-579 (1975).
51. Jordan, V. C. & Dowse, L. J. Tamoxifen as an antitumour agent: effect on oestrogen binding. J. Endocrinol. 68, 297-303 (1976).
52. Jordan, V. C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer 12, 419-424 (1976).
53. Jordan, V. C. & Jaspan, T. Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J. Endocrinol. 68, 453-460 (1976).
54. Kiang, D. T. & Kennedy, B. J. Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann. Intern. Med. 87, 687-690 (1977).
55. NATO. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1, 257-261 (1983).
56. NATO. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation. Br. J. Cancer 57, 608-611 (1987).
57. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467 (1998).
58. Colletta, A. A., Benson, J. R. & Baum, M. Alternative mechanisms of action of antioestrogens. Breast Cancer Res. Treat. 31, 5-9 (1994).
59. Lippman, M. E. & Bolan, G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256, 592-593 (1975).
60. Jordan, V. C. & Allen, K. E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer 16, 239-251 (1980).
61. Jordan, V. C., Dix, C. J. & Allen, K. E. in Adjuvant Therapy of Cancer (eds Salmon, S. E. & Jones, S. E.) 19-26 (Grune & Stratton, Inc., New York, 1979).
62. Jordan, V. C. in Reviews on Endocrine-related Cancer 49-55 (October Supplement) (1978).
63. Jordan, V. C., Allen, K. E. & Dix, C. J. Pharmacology at tamoxifen in laboratory animals. Cancer Treat. Rep. 64, 745-759 (1980).
64. Baum, M. et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 2, 450 (1983).
65. Fisher, B., Dignam, J., Bryant, J. & Wolmark, N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93, 684-690 (2001).
66. Osborne, C. K., Coronado, E. B. & Robinson, J. P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol. 23, 1189-1196 (1987).
67. Gottardis, M. M. & Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48, 5183-5187 (1988).
68. Jordan, V. C., Phelps, E. & Lindgren, J. U. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. 10, 31-35 (1987).
69. Jordan, V. C. & Robinson, S. P. Species-specific pharmacology of antiestrogens: role of metabolism. Fed. Proc. 46, 1870-1874 (1987).
70. Jordan, V. C. Selective estrogen receptor modulation: a personal perspective. Cancer Res. 61, 5683-5687 (2001).
71. Love, R. R. et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 115, 860-864 (1991).
72. Love, R. R. et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl J. Med. 326, 852-856 (1992).
73. Gottardis, M. M. & Jordan, V. C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 47, 4020-4024 (1987).
74. Jordan, V. C., Lababidi, M. K. & Langan-Fahey, S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J. Natl Cancer Inst. 83, 492-496 (1991).
75. CUzick, J. & Baum, M. Tamoxifen and contralateral breast cancer. Lancet 2, 282 (1985).
76. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371-1388 (1998).
77. IBIS Investigators. First results from the International Breast Study: a randomized prevention trial. Lancet 360, 817-824 (2002).
78. Powles, T. J. et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer 60, 126-131 (1989).
79. Powles, T. et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98-101 (1998).
80. Gail, M. H. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879-1886 (1989).
81. Satyaswaroop, P. G., Zaino, R. J. & Mortel, R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res. 44, 4006-4010 (1984).
82. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G. & Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48, 812-815 (1988).
83. Fornander, T. et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1, 117-120 (1989).
84. Fisher, B. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst. 86, 527-537 (1994).
85. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. & Orton, T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53, 3919-3924 (1993).
86. Jordan, V. C. What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective. Ann. Oncol. 6, 29-34 (1995).
87. Ettinger, B. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637-645 (1999).
88. Cummings, S. R. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes at Raloxifene Evaluation. JAMA 281, 2189-2197 (1999).
89. Buzdar, A. U., Marcus, C., Holmes, F., Hug, V. & Hortobagyi, G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45, 344-345 (1988).
90. Jordan, V. C. Designer estrogens. Sci. Am. 279, 60-67 (1998).
91. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the women's health initiative randomized controlled trial. JAMA 288, 321-333 (2002).
92. Wakeling, A. E., Dukes, M. & Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51, 3867-3873 (1991).
93. The ATAC Trialist Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359, 2131-2139 (2002).
94. Osborne, C. K. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results at a North American trial. J. Clin. Oncol. 20, 3386-3395 (2002).
95. Howell, A. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 20, 3396-3403 (2002).
96. McGuire, W. L., Carbone, P. R., Sears M. F. & Escher, G. C. in Oestrogen Receptors in Human Breast Cancer (eds McGuire, W. L., Carbone, P. R. & Volmer, E. P.) 6 (Raven, New York, 1975).